Novartis discovers, develops, manufactures, and markets patent-protected medicines for serious diseases. Its research and commercial activities concentrate on oncology, cardiovascular, renal, immunology, and neuroscience therapies. Healthcare professionals and patients receive these products through hospitals, pharmacies, and specialized distribution channels.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 14,836 | — | 4,041 | 0.5% |
| Q3 2025 | 14,358 | — | 3,928 | -5.8% |
| Q4 2025 | 13,860 | — | 2,409 | -39.1% |
| Q1 2026 | 13,524 | — | 3,156 | -29.9% |
| Q2 2026 | 14,951 | 0.8% | 3,264 | -19.2% |
All markets — KeepWinning global stock screener
Other companies on SMI: Nestlé SA (NESN), ABB Ltd (ABBN), UBS Group AG (UBSG), Compagnie Financière Richemont SA (CFR), Zurich Insurance Group AG (ZURN), Swiss Reinsurance Company Ltd (SREN)